All News
ACR25 Best Abstracts - Day 3
Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at ACR Convergence 2025.
Read Article
Secukinumab vs Ustekinumab in PsA https://t.co/EylYHtRWsj
@synovialjoints Elaborate more on head to head trial in PsA , in a population who failed TNF biologic.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
What's the latest in PsA? https://t.co/I8ZgRQpVy6
Great review for whats new in PsA by @drpnash
Looking forward for Large IL23-Axial study results.
@RheumNow
#ACR25
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Can we catch PsA before it starts?
My take on #ABSTRACT0877 for #ACR25
@RheumNow
https://t.co/Rw2gJ4XSsz
Aurelie Najm AurelieRheumo ( View Tweet)
Sleep Apnea in Psoriatic Arthritis – A Wake Up Call
Fatigue is one of the most disabling symptoms in psoriatic arthritis (PsA), yet its causes are often underexplored. At #ACR25, Abstract #0549, a possible hidden contributor was studied: obstructive sleep apnea (OSA). In a https://t.co/E3cy1Uss73
Dr. John Cush RheumNow ( View Tweet)
Head to head study of Secukinumab vs Ustekinumab. In TNFi-experienced PsA patients, the AgAIN trial shows secukinumab performed better than ustekinumab in HAQ-DI response (57.1% vs 27.0%, p=0.002) and across all endpoints (joint counts, pain, and skin outcomes). Fewer https://t.co/CDCWkLF5TW
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
52wks data of IZOKIPEB affibody IL17Ai RCT 2b/3 PsA
Primary ACR 50 16wks
Crossover 52 wks IZO 160 Q2W, IZO 160 QW, PBO-> IZO 160 QW
ACR50 50% 57% 51%
ACR70 36% 42% 42%
PASI100 55% 64% 58%
MDA 47% 52% 47%
No specific enthesitis data presented
No new safety signal
Next https://t.co/J18rSTmyze
Aurelie Najm AurelieRheumo ( View Tweet)
In PsA, a predictive model using routine labs (NLR, LMR, ESR, C3, baseline DAPSA) identified TNFi responders with 100% sensitivity and 0.861 AUC. Supports biomarker-driven personalization of PsA treatment. Abstract#2371 @RheumNow #ACR25 https://t.co/lojQFfWsJi
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Eder et al. Deucravacitinib in PsA from POETYK-PsA stuides. Male and female patients had similar response rates at week 16. ACR 20 57% vs 51%, ACR50 27% vs 27%, ACR70 12% vs 10%, MDA 24% vs 20%. @RheumNow #ACR25 Abstr#2356 https://t.co/bImzTA7uUC
Richard Conway RichardPAConway ( View Tweet)
Gladman et al. PsA patients treated with guselkumab in DISCOVER-2. Male patients had more radiographic progression. Males exhibit stronger relationship between early joint response and lower subsequent rates radiographic progression. @RheumNow #ACR25 Abstr#2345 https://t.co/TSNwesvPzj
Richard Conway RichardPAConway ( View Tweet)
Late breaking: secukinumab out-performs ustekinumab in PsA pt who have failed TNF therapy
RCT of 119 pt
57.1% response at wk 28 in SEC
27% response at wk 28 in UST
Numerically lower adverse events leading to d/c in SEC
@RheumNow #ACR25 #ACRBest Abst LB06 https://t.co/wDxtscP2ku
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Benson et al. Clinical features that predict CV risk in PsA. Median 3.53 year follow up. 56 CV events. 766 patients. Dactylitis emerged as key predictor in adjusted models. @RheumNow #ACR25 Abstr#2317 https://t.co/5O3G7vGYbq
Richard Conway RichardPAConway ( View Tweet)
Meta-analysis of 3 RCTs (n=1990) shows IL-17i offers comparable joint response but superior skin clearance vs adalimumab in biologic-naive PsA. IL-17i also had fewer discontinuations due to adverse events. Supports sequencing of biologics through different mechanisms of action in https://t.co/SJgFUMxWVb
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Heydari-Kamjani et al. TriNetX study. 28973 PsA patients. IL-17i and IL-23i lower rates stroke, MI, DVT/PE than TNFi. IL-12/23i higher rate of stroke vs TNFi. @RheumNow #ACR25 Abstr#2363 https://t.co/fNHaxyYPCP
Richard Conway RichardPAConway ( View Tweet)
Molina et al. 52 weeks of MANHATTAN study. Guselkumab vs second TNFi after failure 1st TNFi in PsA. MDA 52% vs 33%. Remission/LDA 67% vs 62%. @RheumNow #ACR25 Abstr#2373 https://t.co/qdtOlKLfNU
Richard Conway RichardPAConway ( View Tweet)
Hojiej et al. Prevalence and Impact of lifestyle factors in PsA. Lifestyle factors impacted disease activity. Cumulative effect of increasing number of factors @RheumNow #ACR25 Abstr#2309 https://t.co/oDGQyLBRDO
Richard Conway RichardPAConway ( View Tweet)
In DISCOVER-2, male PsA patients had greater radiographic progression than females despite similar baseline scores. Early joint response (W8 cDAPSA LDA) was linked to less progression more strongly in men. Highlights the sex differences in PsA outcomes. Abstract#2345 @RheumNow https://t.co/zIo59FYPVg
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Gender differences in p/axSpA in Turkiye from ASAS-PerSpA:
Males - early onset IBP (<45yrs); sacroiliitis on CR, HLA-B27+ (vs. females)
Females - peripheral dse, enthesitis, Pso, dactylitis; ⬆️dse activity, FM (vs. males)
Individualize & optimize tx.
#ACR25 @RheumNow Abs2322 https://t.co/vcisNguJLB
sheila RHEUMarampa ( View Tweet)
#ClinicalPearl
Pts w #SpA ex #PsA May have
👇
#sicca #dry #eyes #dry mouth
Inflamed gallbladder without calculi
👇
Can be associated w #autoimmune disease
#POTS can be initial presentation of #SjD
IgA vasculitis—May have #cancer
#Secrets & #Pearls #ACR25 @RheumNow @ACRheum https://t.co/4SAqVYjnrD
Janet Pope Janetbirdope ( View Tweet)
Late-Breaking Trials in axSpA and PsA https://t.co/Fw8wiAPLoN
The amazing @Janetbirdope discussing head to head trials in Axial SpA and PsA with primary failure to TNF.
To switch to another TNF or IL17?
IL17 for my PsA patient for sure.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
